1. Generics Bulletin
  2. >>Products

Cranbury Forms From Tris Pharma, With First Generic DMD Treatment Deflazacort

Tris Pharma’s Jannet Penner Named As Cranbury’s President; 20 Generics Marketed

 
• By Dean Rudge

Tris Pharma has handed over the keys to its generics portfolio and pipeline to a new subsidiary, Cranbury Pharmaceuticals, which has debuted competition to PTC Therapeutics’ Emflaza (deflazacort) oral suspension.

• Source: Shutterstock

Cranbury Pharmaceuticals has begun shipping the first US generic version of PTC Therapeutics’ Emflaza (deflazacort) oral suspension for the treatment of Duchenne muscular dystrophy, after the brand’s seven-year period of orphan drug exclusivity for treatment of DMD in patients five years and older expired in February this year.

The New Jersey-based company is a new subsidiary of Tris Pharma, which has handed over its generics portfolio and pipeline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin